

Purified anti-human EGFR

Catalog # / Size: 2364505 / 25 µg
2364510 / 100 µg

Clone: AY13

Isotype: Mouse IgG1, κ


Immunogen: Non-small cell lung cancer (NSCLC) cell line NCI-H322

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.5




HeLa cells were fixed with 2% PFA for ten minutes, permeabilized with 0.5% Triton X-100 for five minutes, and blocked with 5% FBS for 30 minutes. Then the cells were intracellularly stained with 2 microg/mL anti-human EGFR Antibody (clone AY13) followed

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. For immunofluorescence microscopy, the suggested use of this reagent is 1-5 microg per ml. It is recommended that the reagent be titrated for optimal performance for each application.



Human cervical cancer cell line HeLa was stained with purified EGFR (clone AY13) (filled histogram) or mouse IgG1, κ isotype control (open histogram), followed by anti-mouse IgG PE.

Application References: 1. Yamaguchi M, *et al.* 2009. The 15th Annual Meeting Japan Society of Gene Therapy. p1056. Abstract 92.

Description: Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and member of the protein kinase superfamily that regulates cell growth and differentiation. EGFR binds EGF, TGF-α, amphiregulin, βcellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor - all members of the EGF family. Ligand binding induces EGFR dimerization and autophosphorylation, initiating the MAPK, Akt, and JNK signaling pathways. EGFR is expressed by epithelial and endothelial cells and is frequently expressed by

epithelial carcinomas.

**Antigen
References:**

1. da Cunha Santos G, *et al.* 2011. *Annu. Rev. Pathol.* 6:49.
2. Gusterson BA and Hunter KD. 2009. *Lancet Oncol.* 10:522.
3. Mano M and Humblet Y. 2008. *Nat. Clin. Pract. Oncol.* 5:415.
4. Pao W and Chm